Achieving Rapid, High-Titer Expression for Next-Generation Biologics
Summary: Catalent’s cell line development Lightning technology genetically engineers high-expressing, highly stable production cell lines. This standardized, scalable platform for protein manufacturing offers consistent performance from laboratory to GMP-scale bioreactors and enables rapid scale-up. The technology is a proven approach to generate cell lines across a variety of protein types, from standard monoclonal antibodies (mAbs) to next-generation biologics, including bispecific and multi-specific antibodies, multi-gene, and other complex molecules. This executive summary addresses the growing challenge for biologics manufacturers to create effective cell line development technologies that ensure stable, high-titer expression across various protein formats, along with the solutions provided by Catalent for our customers.